Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Subtype-specific regulatory network rewiring in acute myeloid leukemia.

Assi SA, Imperato MR, Coleman DJL, Pickin A, Potluri S, Ptasinska A, Chin PS, Blair H, Cauchy P, James SR, Zacarias-Cabeza J, Gilding LN, Beggs A, Clokie S, Loke JC, Jenkin P, Uddin A, Delwel R, Richards SJ, Raghavan M, Griffiths MJ, Heidenreich O, Cockerill PN, Bonifer C.

Nat Genet. 2019 Jan;51(1):151-162. doi: 10.1038/s41588-018-0270-1. Epub 2018 Nov 12.

2.

Temporal autoregulation during human PU.1 locus SubTAD formation.

Schuetzmann D, Walter C, van Riel B, Kruse S, König T, Erdmann T, Tönges A, Bindels E, Weilemann A, Gebhard C, Wethmar K, Perrod C, Minderjahn J, Rehli M, Delwel R, Lenz G, Gröschel S, Dugas M, Rosenbauer F.

Blood. 2018 Dec 20;132(25):2643-2655. doi: 10.1182/blood-2018-02-834721. Epub 2018 Oct 12.

PMID:
30315124
3.

Correction to: EVI2B is a C/EBPα target gene required for granulocytic differentiation and functionality of hematopoietic progenitors.

Zjablovskaja P, Kardosova M, Danek P, Angelisova P, Benoukraf T, Wurm AA, Kalina T, Sian S, Balastik M, Delwel R, Brdicka T, Tenen DG, Behre G, Fiore F, Malissen B, Horejsi V, Alberich-Jorda M.

Cell Death Differ. 2019 Jan;26(1):198. doi: 10.1038/s41418-018-0146-z.

4.

Puzzling pieces of chromosome 7 loss or deletion.

Schneider RK, Delwel R.

Blood. 2018 Jun 28;131(26):2871-2872. doi: 10.1182/blood-2018-04-844746. No abstract available.

5.

The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia.

Numata A, Kwok HS, Kawasaki A, Li J, Zhou QL, Kerry J, Benoukraf T, Bararia D, Li F, Ballabio E, Tapia M, Deshpande AJ, Welner RS, Delwel R, Yang H, Milne TA, Taneja R, Tenen DG.

Nat Commun. 2018 Apr 24;9(1):1622. doi: 10.1038/s41467-018-03854-0.

6.

Publisher Correction: miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.

Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJM, Delwel R, Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen J.

Nat Commun. 2018 Apr 10;9:16192. doi: 10.1038/ncomms16192.

7.

Lethal neonatal bone marrow failure syndrome with multiple congenital abnormalities, including limb defects, due to a constitutional deletion of 3' MECOM.

van der Veken LT, Maiburg MC, Groenendaal F, van Gijn ME, Bloem AC, Erpelinck C, Gröschel S, Sanders MA, Delwel R, Bierings MB, Buijs A.

Haematologica. 2018 Apr;103(4):e173-e176. doi: 10.3324/haematol.2017.185033. Epub 2018 Feb 8. No abstract available.

8.

Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.

Glass JL, Hassane D, Wouters BJ, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer AM, Meydan C, Qin T, Fall M, Alonso A, Guzman ML, Valk PJM, Thompson CB, Levine R, Elemento O, Delwel R, Melnick A, Figueroa ME.

Cancer Discov. 2017 Aug;7(8):868-883. doi: 10.1158/2159-8290.CD-16-1032. Epub 2017 Apr 13.

9.

EVI2B is a C/EBPα target gene required for granulocytic differentiation and functionality of hematopoietic progenitors.

Zjablovskaja P, Kardosova M, Danek P, Angelisova P, Benoukraf T, Wurm AA, Kalina T, Sian S, Balastik M, Delwel R, Brdicka T, Tenen DG, Behre G, Fiore F, Malissen B, Horejsi V, Alberich-Jorda M.

Cell Death Differ. 2017 Apr;24(4):705-716. doi: 10.1038/cdd.2017.6. Epub 2017 Feb 10. Erratum in: Cell Death Differ. 2019 Jan;26(1):198.

10.

Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation.

Avellino R, Delwel R.

Blood. 2017 Apr 13;129(15):2083-2091. doi: 10.1182/blood-2016-09-687822. Epub 2017 Feb 8. Review.

11.

Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors.

Riemke P, Czeh M, Fischer J, Walter C, Ghani S, Zepper M, Agelopoulos K, Lettermann S, Gebhardt ML, Mah N, Weilemann A, Grau M, Gröning V, Haferlach T, Lenze D, Delwel R, Prinz M, Andrade-Navarro MA, Lenz G, Dugas M, Müller-Tidow C, Rosenbauer F.

EMBO J. 2016 Nov 15;35(22):2399-2416. Epub 2016 Aug 29.

12.

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.

Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, Lewis ID, To LB, Delwel R, Löwenberg B, Döhner H, Döhner K, Guzman ML, Hassane DC, Roboz GJ, Grimwade D, Valk PJ, D'Andrea RJ, Carroll M, Park CY, Neuberg D, Levine R, Melnick AM, Mason CE.

Nat Med. 2016 Jul;22(7):792-9. doi: 10.1038/nm.4125. Epub 2016 Jun 20.

13.

MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis.

Yokoyama T, Nakatake M, Kuwata T, Couzinet A, Goitsuka R, Tsutsumi S, Aburatani H, Valk PJ, Delwel R, Nakamura T.

J Clin Invest. 2016 May 2;126(5):1664-78. doi: 10.1172/JCI81516. Epub 2016 Mar 28.

14.

DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.

Meyer SE, Qin T, Muench DE, Masuda K, Venkatasubramanian M, Orr E, Suarez L, Gore SD, Delwel R, Paietta E, Tallman MS, Fernandez H, Melnick A, Le Beau MM, Kogan S, Salomonis N, Figueroa ME, Grimes HL.

Cancer Discov. 2016 May;6(5):501-15. doi: 10.1158/2159-8290.CD-16-0008. Epub 2016 Mar 25.

15.

An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation.

Avellino R, Havermans M, Erpelinck C, Sanders MA, Hoogenboezem R, van de Werken HJ, Rombouts E, van Lom K, van Strien PM, Gebhard C, Rehli M, Pimanda J, Beck D, Erkeland S, Kuiken T, de Looper H, Gröschel S, Touw I, Bindels E, Delwel R.

Blood. 2016 Jun 16;127(24):2991-3003. doi: 10.1182/blood-2016-01-695759. Epub 2016 Mar 10.

16.

A somatic mutation of GFI1B identified in leukemia alters cell fate via a SPI1 (PU.1) centered genetic regulatory network.

Anguita E, Gupta R, Olariu V, Valk PJ, Peterson C, Delwel R, Enver T.

Dev Biol. 2016 Mar 15;411(2):277-286. doi: 10.1016/j.ydbio.2016.02.002. Epub 2016 Feb 3.

17.

Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.

Wouters BJ, Delwel R.

Blood. 2016 Jan 7;127(1):42-52. doi: 10.1182/blood-2015-07-604512. Epub 2015 Dec 10. Review.

18.

Congenital thrombocytopenia in a neonate with an interstitial microdeletion of 3q26.2q26.31.

Bouman A, Knegt L, Gröschel S, Erpelinck C, Sanders M, Delwel R, Kuijpers T, Cobben JM.

Am J Med Genet A. 2016 Feb;170A(2):504-509. doi: 10.1002/ajmg.a.37451. Epub 2015 Nov 10.

PMID:
26554871
19.

Erratum: Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.

Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KV, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G.

Nat Chem Biol. 2015 Oct;11(10):815. doi: 10.1038/nchembio1015-815b. No abstract available.

PMID:
26379026
20.

Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.

Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KVM, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G.

Nat Chem Biol. 2015 Aug;11(8):571-578. doi: 10.1038/nchembio.1859. Epub 2015 Jul 13. Erratum in: Nat Chem Biol. 2015 Oct;11(10):815.

21.

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.

Kühnl A, Valk PJ, Sanders MA, Ivey A, Hills RK, Mills KI, Gale RE, Kaiser MF, Dillon R, Joannides M, Gilkes A, Haferlach T, Schnittger S, Duprez E, Linch DC, Delwel R, Löwenberg B, Baldus CD, Solomon E, Burnett AK, Grimwade D.

Blood. 2015 May 7;125(19):2985-94. doi: 10.1182/blood-2014-12-613703. Epub 2015 Mar 24.

22.

Myeloid disorders arise in Dnmt3a-null marrow.

Delwel R.

Blood. 2015 Jan 22;125(4):585-6. doi: 10.1182/blood-2014-12-614164. No abstract available.

23.

Whole-transcriptome analysis of endothelial to hematopoietic stem cell transition reveals a requirement for Gpr56 in HSC generation.

Solaimani Kartalaei P, Yamada-Inagawa T, Vink CS, de Pater E, van der Linden R, Marks-Bluth J, van der Sloot A, van den Hout M, Yokomizo T, van Schaick-Solernó ML, Delwel R, Pimanda JE, van IJcken WF, Dzierzak E.

J Exp Med. 2015 Jan 12;212(1):93-106. doi: 10.1084/jem.20140767. Epub 2014 Dec 29.

24.

Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.

Gröschel S, Sanders MA, Hoogenboezem R, Zeilemaker A, Havermans M, Erpelinck C, Bindels EM, Beverloo HB, Döhner H, Löwenberg B, Döhner K, Delwel R, Valk PJ.

Blood. 2015 Jan 1;125(1):133-9. doi: 10.1182/blood-2014-07-591461. Epub 2014 Nov 7.

25.

The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells.

Staber PB, Zhang P, Ye M, Welner RS, Levantini E, Di Ruscio A, Ebralidze AK, Bach C, Zhang H, Zhang J, Vanura K, Delwel R, Yang H, Huang G, Tenen DG.

Blood. 2014 Oct 9;124(15):2391-9. doi: 10.1182/blood-2014-01-550855. Epub 2014 Sep 3.

26.

A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.

Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, van der Velden VHJ, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R.

Cell. 2014 Apr 10;157(2):369-381. doi: 10.1016/j.cell.2014.02.019. Epub 2014 Apr 3.

27.

Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling.

Taskesen E, Havermans M, van Lom K, Sanders MA, van Norden Y, Bindels E, Hoogenboezem R, Reinders MJ, Figueroa ME, Valk PJ, Löwenberg B, Melnick A, Delwel R.

Blood. 2014 May 22;123(21):3327-35. doi: 10.1182/blood-2013-07-512855. Epub 2014 Mar 25.

28.

PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.

Zhou J, Wu J, Li B, Liu D, Yu J, Yan X, Zheng S, Wang J, Zhang L, Zhang L, He F, Li Q, Chen A, Zhang Y, Zhao X, Guan Y, Zhao X, Yan J, Ni J, Nobrega MA, Löwenberg B, Delwel R, Valk PJ, Kumar A, Xie L, Tenen DG, Huang G, Wang QF.

Leukemia. 2014 Jul;28(7):1436-48. doi: 10.1038/leu.2013.384. Epub 2013 Dec 26.

29.

Hypergeometric analysis of tiling-array and sequence data: detection and interpretation of peaks.

Taskesen E, Hoogeboezem R, Delwel R, Reinders MJ.

Adv Appl Bioinform Chem. 2013 Oct 25;6:55-62. doi: 10.2147/AABC.S51271. eCollection 2013.

30.

Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia.

Zhang H, Alberich-Jorda M, Amabile G, Yang H, Staber PB, Di Ruscio A, Welner RS, Ebralidze A, Zhang J, Levantini E, Lefebvre V, Valk PJ, Delwel R, Hoogenkamp M, Nerlov C, Cammenga J, Saez B, Scadden DT, Bonifer C, Ye M, Tenen DG.

Cancer Cell. 2013 Nov 11;24(5):575-88. doi: 10.1016/j.ccr.2013.09.018. Epub 2013 Oct 31. Erratum in: Cancer Cell. 2014 Feb 10;25(2):257. Diruscio, Annalisa [corrected to Di Ruscio, Annalisa].

31.

The gene signature in CCAAT-enhancer-binding protein α dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors.

Liss A, Ooi CH, Zjablovskaja P, Benoukraf T, Radomska HS, Ju C, Wu M, Balastik M, Delwel R, Brdicka T, Tan P, Tenen DG, Alberich-Jorda M.

Haematologica. 2014 Apr;99(4):697-705. doi: 10.3324/haematol.2013.093278. Epub 2013 Oct 25.

32.

HAT: a novel statistical approach to discover functional regions in the genome.

Taskesen E, Wouters B, Delwel R.

Methods Mol Biol. 2013;1067:125-41. doi: 10.1007/978-1-62703-607-8_9.

PMID:
23975790
33.

The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.

Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, Gaidzik VI, Paschka P, Corbacioglu A, Göhring G, Kündgen A, Held G, Götze K, Vellenga E, Kuball J, Schanz U, Passweg J, Pabst T, Maertens J, Ossenkoppele GJ, Delwel R, Döhner H, Cornelissen JJ, Döhner K, Löwenberg B.

Blood. 2013 Aug 29;122(9):1576-82. doi: 10.1182/blood-2013-05-503847. Epub 2013 Jul 17.

34.

The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.

Song SJ, Ito K, Ala U, Kats L, Webster K, Sun SM, Jongen-Lavrencic M, Manova-Todorova K, Teruya-Feldstein J, Avigan DE, Delwel R, Pandolfi PP.

Cell Stem Cell. 2013 Jul 3;13(1):87-101. doi: 10.1016/j.stem.2013.06.003.

35.

Phosphorylation of the leukemic oncoprotein EVI1 on serine 196 modulates DNA binding, transcriptional repression and transforming ability.

White DJ, Unwin RD, Bindels E, Pierce A, Teng HY, Muter J, Greystoke B, Somerville TD, Griffiths J, Lovell S, Somervaille TC, Delwel R, Whetton AD, Meyer S.

PLoS One. 2013 Jun 12;8(6):e66510. doi: 10.1371/journal.pone.0066510. Print 2013.

36.

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher MD, Maharry KS, Sun M, Yang X, Huang H, Jiang X, Sauerland MC, Büchner T, Hiddemann W, Elkahloun A, Neilly MB, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Döhner K, Bullinger L, Liu PP, Delwel R, Marcucci G, Lowenberg B, Bloomfield CD, Rowley JD, Bohlander SK, Chen J.

J Clin Oncol. 2013 Mar 20;31(9):1172-81. doi: 10.1200/JCO.2012.44.3184. Epub 2013 Feb 4.

37.

Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.

Irandoust M, Alvarez Zarate J, Hubeek I, van Beek EM, Schornagel K, Broekhuizen AJ, Akyuz M, van de Loosdrecht AA, Delwel R, Valk PJ, Sonneveld E, Kearns P, Creutzig U, Reinhardt D, de Bont ES, Coenen EA, van den Heuvel-Eibrink MM, Zwaan CM, Kaspers GJ, Cloos J, van den Berg TK.

PLoS One. 2013;8(1):e52143. doi: 10.1371/journal.pone.0052143. Epub 2013 Jan 8.

38.

PBX3 is an important cofactor of HOXA9 in leukemogenesis.

Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H, Jiang X, Hong GM, Kunjamma RB, Ren H, He C, Wang CZ, Elkahloun AG, Valk PJ, Döhner K, Neilly MB, Bullinger L, Delwel R, Löwenberg B, Liu PP, Morgan R, Rowley JD, Yuan CS, Chen J.

Blood. 2013 Feb 21;121(8):1422-31. doi: 10.1182/blood-2012-07-442004. Epub 2012 Dec 20.

39.

Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.

Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJ, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA.

Leukemia. 2013 Apr;27(4):852-60. doi: 10.1038/leu.2012.363. Epub 2012 Dec 13.

40.

C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia.

Alberich-Jordà M, Wouters B, Balastik M, Shapiro-Koss C, Zhang H, Di Ruscio A, Radomska HS, Ebralidze AK, Amabile G, Ye M, Zhang J, Lowers I, Avellino R, Melnick A, Figueroa ME, Valk PJ, Delwel R, Tenen DG.

J Clin Invest. 2012 Dec;122(12):4490-504. doi: 10.1172/JCI65102. Epub 2012 Nov 19. Erratum in: J Clin Invest. 2013 Jan 2;123(1):526. DiRuscio, Annalisa [corrected to Di Ruscio, Annalisa].

41.

Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.

Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Löwenberg B, Döhner K, Döhner H, Delwel R.

J Clin Oncol. 2013 Jan 1;31(1):95-103. doi: 10.1200/JCO.2011.41.5505. Epub 2012 Sep 24.

PMID:
23008312
42.

Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα.

Radomska HS, Alberich-Jordà M, Will B, Gonzalez D, Delwel R, Tenen DG.

J Clin Invest. 2012 Aug;122(8):2955-66. doi: 10.1172/JCI43354. Epub 2012 Jul 17.

43.

Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia.

Akalin A, Garrett-Bakelman FE, Kormaksson M, Busuttil J, Zhang L, Khrebtukova I, Milne TA, Huang Y, Biswas D, Hess JL, Allis CD, Roeder RG, Valk PJ, Löwenberg B, Delwel R, Fernandez HF, Paietta E, Tallman MS, Schroth GP, Mason CE, Melnick A, Figueroa ME.

PLoS Genet. 2012;8(6):e1002781. doi: 10.1371/journal.pgen.1002781. Epub 2012 Jun 21.

44.

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.

Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT.

Nat Med. 2012 Jul;18(7):1118-22. doi: 10.1038/nm.2819.

45.

ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia.

Damm F, Wagner K, Görlich K, Morgan M, Thol F, Yun H, Delwel R, Valk PJM, Löwenberg B, Heuser M, Ganser A, Krauter J.

Br J Haematol. 2012 Jul;158(2):208-215. doi: 10.1111/j.1365-2141.2012.09144.x. Epub 2012 May 9.

PMID:
22568493
46.

EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.

Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Döhner H, Hudson WA, Kersey JH, Delwel R, Kumar AR.

Blood. 2012 Jun 14;119(24):5838-49. doi: 10.1182/blood-2011-11-393827. Epub 2012 May 2.

47.

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.

Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, Rockova V, Sanders M, Abbas S, Figueroa ME, Zeilemaker A, Melnick A, Löwenberg B, Valk PJ, Delwel R.

Blood. 2012 Jun 14;119(24):5824-31. doi: 10.1182/blood-2011-07-367961. Epub 2012 Apr 5.

48.

An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model.

Bergerson RJ, Collier LS, Sarver AL, Been RA, Lugthart S, Diers MD, Zuber J, Rappaport AR, Nixon MJ, Silverstein KA, Fan D, Lamblin AF, Wolff L, Kersey JH, Delwel R, Lowe SW, O'Sullivan MG, Kogan SC, Adams DJ, Largaespada DA.

Blood. 2012 May 10;119(19):4512-23. doi: 10.1182/blood-2010-04-281428. Epub 2012 Mar 16.

49.

Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia.

Zebisch A, Wölfler A, Fried I, Wolf O, Lind K, Bodner C, Haller M, Drasche A, Pirkebner D, Matallanas D, Rath O, Blyth K, Delwel R, Taskesen E, Quehenberger F, Kolch W, Troppmair J, Sill H.

Leukemia. 2012 Aug;26(8):1842-9. doi: 10.1038/leu.2012.61. Epub 2012 Mar 5.

PMID:
22388727
50.

miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.

Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJ, Delwel R, Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen J.

Nat Commun. 2012 Feb 21;3:688. doi: 10.1038/ncomms1681. Erratum in: Nat Commun. 2018 Apr 10;9:16192.

Supplemental Content

Loading ...
Support Center